文献综述(Review)

基于树突状细胞的肝细胞癌免疫治疗研究进展

Published at: 2015年第24卷第7期

舒常发 1 , 刘锐 1 , 李清龙 2
1 中南大学湘雅医学院,湖南 长沙 410013
2 中南大学湘雅二医院 普通外科,湖南 长沙 410011
通讯作者 清龙 李 Email: liqinglonga@sina.com
DOI: 10.3978/j.issn.1005-6947.10.3978/j.issn.1005-6947.2015.07.019
基金:

摘要

肝细胞癌(HCC)是最常见的原发性肝癌,目前,免疫疗法已成为继手术治疗、放射治疗、化学治疗之后的第4 种治疗HCC 的手段。许多研究证明,免疫治疗可以提高机体的免疫功能,以减少HCC的复发和转移、延长患者生存期。树突状细胞(DC)是体内功能最强大的抗原提呈细胞,在机体的抗肿瘤免疫应答中发挥着重要作用。DC 抗肿瘤疫苗、DC- 细胞因子诱导的杀伤细胞细胞疗法、DC 免疫治疗联用肝动脉化疗栓塞术和光动力疗法等以DC 为基础的方式已成为HCC 免疫治疗研究中的热点,并展现出良好的前景。笔者将对近几年基于树突状细胞的HCC 免疫治疗的研究进展进行综述。


Research progress of dendritic cell-based immunotherapy for hepatocellular carcinoma

Abstract

Hepatocellular carcinoma (HCC) is the most common primary liver cancer. At present, immunotherapy has become the fourth treatment for HCC following surgery, radiotherapy and chemotherapy. Many studies have proven that immunotherapy can improve the systemic immunological function to reduce the recurrence and metastasis of HCC and prolong the survival time for HCC patients. Dendritic cells (DC) are the most powerful antigen-presenting cells in vivo and play an important role in anti-tumor immune response. The DC-based immunotherapy including DC anti-tumor vaccine, DC-cytokine induced killer cells immunotherapy and DC immunotherapy combined with transcatheter arterial chemoembolization or photodynamic therapy has become the research focus in immunotherapy of HCC and also shown a promising direction. This review concentrates on the research progress of DC-based immunotherapy for HCC in recent years.


comments powered by Disqus

全文

引用

引用本文: 常发 舒, 锐 刘, 清龙 李. 基于树突状细胞的肝细胞癌免疫治疗研究进展[J]. 中国普通外科杂志, 2015, 24(7): 1022-1026.
Cite this article as: SHU Changfa, LIU Rui, LI Qinglong . Research progress of dendritic cell-based immunotherapy for hepatocellular carcinoma[J]. Chin J Gen Surg, 2015, 24(7): 1022-1026.